Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-03, Vol.388 (12), p.1080-1091
Hauptverfasser:	Silverberg, Jonathan I., Guttman-Yassky, Emma, Thaçi, Diamant, Irvine, Alan D., Stein Gold, Linda, Blauvelt, Andrew, Simpson, Eric L., Chu, Chia-Yu, Liu, Zhuqing, Gontijo Lima, Renata, Pillai, Sreekumar G., Seneschal, Julien
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adolescents Adult Adults Age Allergy Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Atopic dermatitis Clinical Medicine Clinical Medicine General Clinical trials Conjunctivitis Cytokines Dermatitis Dermatitis, Atopic - complications Dermatitis, Atopic - drug therapy Dermatitis, Atopic - immunology Dermatology Dermatology General Double-Blind Method Double-blind studies Drug therapy Eczema Humans Immunoglobulin A Immunoglobulin G Immunoglobulin G - immunology Immunology Immunology General Infant Inflammatory Disease Interleukin 13 Interleukin-13 - antagonists & inhibitors Interleukin-13 - immunology Light therapy Monoclonal antibodies Pathogenesis Patient safety Placebos Pruritus Pruritus - drug therapy Pruritus - etiology Pruritus - immunology Quality of life Severity of Illness Index Skin Skin - drug effects Skin - immunology Sleep T-Cells Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both trials included a 16-week induction period and a 36-week maintenance period. Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2206714